{"id":409445,"date":"2021-01-06T08:18:16","date_gmt":"2021-01-06T13:18:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=409445"},"modified":"2021-01-06T08:18:16","modified_gmt":"2021-01-06T13:18:16","slug":"silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/","title":{"rendered":"Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>Englewood Cliffs, NJ, Jan.  06, 2021  (GLOBE NEWSWIRE) &#8212; <\/strong>Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent and Trademark Office in use for patients suffering with cancer. Silo Pharma\u2019s patent applications relates to using a novel peptide with Psilocybin as a therapeutic.<\/p>\n<p align=\"justify\">Eric Weisblum, CEO of Silo Pharma, Inc, stated \u201cWe are excited about this opportunity as we continue to execute our plan to bring novel therapeutics to patients inflicted with neurological disorders and rare diseases, which we hope will bring about breakthroughs that can lead to improved care. This agreement is structured to provide $500,000 in an upfront cash payment as well as equity currently valued at $500,000 from a NASDAQ listed company. The Agreement also provides for Silo to collect royalties should the technology be commercialized.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Silo Pharma<\/strong><br \/>\n        <br \/>Silo Pharma. Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders. Silo\u2019s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.\u00a0 For more information, visit\u00a0www.silopharma.com<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor and Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This news release contains &#8220;forward-looking statements&#8221; within the meaning of the \u201csafe-harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words \u201ccould\u201d, \u201cbelieve\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201ccontinue\u201d, \u201cpredict\u201d, \u201cpotential\u201d and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (\u201cSilo\u201d or \u201cthe Company\u201d) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company\u2019s technology platforms, retaining and expanding the Company\u2019s customer base, fluctuations in consumer spending on the Company\u2019s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.<\/p>\n<p>\n        <u>Investor Relations Contact:<\/u>\u00a0<br \/> Hayden IR\u00a0<br \/> Brett Maas\u00a0<br \/> 646-536-7331\u00a0<br \/> Email: brett@haydenir.com<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTQ4NSMzOTA3MDIzIzUwMDA2OTMzOQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/67197824-e4ac-4158-8db1-6d98bc21b8ee\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Englewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent and Trademark Office in use for patients suffering with cancer. Silo Pharma\u2019s patent applications relates to using a novel peptide with Psilocybin as a therapeutic. Eric Weisblum, CEO of Silo Pharma, Inc, stated \u201cWe are excited about this opportunity as we continue to execute our plan to bring novel therapeutics to patients inflicted with neurological disorders and rare diseases, which we hope will bring about breakthroughs &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-409445","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Englewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent and Trademark Office in use for patients suffering with cancer. Silo Pharma\u2019s patent applications relates to using a novel peptide with Psilocybin as a therapeutic. Eric Weisblum, CEO of Silo Pharma, Inc, stated \u201cWe are excited about this opportunity as we continue to execute our plan to bring novel therapeutics to patients inflicted with neurological disorders and rare diseases, which we hope will bring about breakthroughs &hellip; Continue reading &quot;Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-06T13:18:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTQ4NSMzOTA3MDIzIzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities\",\"datePublished\":\"2021-01-06T13:18:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\\\/\"},\"wordCount\":482,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTQ4NSMzOTA3MDIzIzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\\\/\",\"name\":\"Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTQ4NSMzOTA3MDIzIzUwMDA2OTMzOQ==\",\"datePublished\":\"2021-01-06T13:18:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTQ4NSMzOTA3MDIzIzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTQ4NSMzOTA3MDIzIzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities - Market Newsdesk","og_description":"Englewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent and Trademark Office in use for patients suffering with cancer. Silo Pharma\u2019s patent applications relates to using a novel peptide with Psilocybin as a therapeutic. Eric Weisblum, CEO of Silo Pharma, Inc, stated \u201cWe are excited about this opportunity as we continue to execute our plan to bring novel therapeutics to patients inflicted with neurological disorders and rare diseases, which we hope will bring about breakthroughs &hellip; Continue reading \"Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-06T13:18:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTQ4NSMzOTA3MDIzIzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities","datePublished":"2021-01-06T13:18:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/"},"wordCount":482,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTQ4NSMzOTA3MDIzIzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/","name":"Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTQ4NSMzOTA3MDIzIzUwMDA2OTMzOQ==","datePublished":"2021-01-06T13:18:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTQ4NSMzOTA3MDIzIzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTQ4NSMzOTA3MDIzIzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=409445"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409445\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=409445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=409445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=409445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}